Related Experiment Video

Updated: Jun 7, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Pregnane X receptor as a therapeutic target to inhibit androgen activity

Bin Zhang1, Qiuqiong Cheng, Zhimin Ou

  • 1Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.

Endocrinology
|October 22, 2010
PubMed

Insights

Pregnane X receptor (PXR) activation reduces androgen activity by boosting androgen metabolism. This PXR-mediated pathway offers a new therapeutic target for hormone-dependent prostate cancer treatment.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Androgen receptor signaling is crucial in prostate cancer development.
  • Androgen deprivation is a primary endocrine therapy for hormone-dependent prostate cancer.

Purpose of the Study:

  • To investigate a novel pregnane X receptor (PXR)-mediated mechanism for reducing androgenic tone.
  • To explore PXR's role in androgen metabolism and its therapeutic potential in prostate cancer.

Main Methods:

  • Utilized genetic (PXR transgene) and pharmacological (PXR agonist) activation of PXR in mouse models.
  • Assessed androgen-dependent prostate regeneration and expression of metabolic enzymes (CYP3A, SULT2A1).
  • Investigated PXR agonist (rifampicin) effects on human prostate cancer cell lines (LAPC-4, LA99) and employed gene silencing techniques (shRNA, siRNA).

Main Results:

  • PXR activation lowered androgenic activity and inhibited prostate regeneration in mice.
  • PXR induction upregulated CYP3A and SULT2A1, enzymes involved in androgen metabolic deactivation.
  • Rifampicin inhibited androgen-dependent LAPC-4 cell proliferation, with effects dependent on PXR and SULT2A1 expression.

Conclusions:

  • Discovered a novel function of PXR in regulating androgen homeostasis.
  • PXR activation represents a potential therapeutic strategy to reduce androgen activity.
  • PXR may serve as a novel target for treating and preventing hormone-dependent prostate cancer.

More Related Videos

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...